RWM
VRTX icon

Ruedi Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Ruedi Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1
Closed -$485 – 313
2025
Q1 		$485 Hold
1
– – ﹤0.01% 310
2024
Q4 		$403 Hold
1
– – ﹤0.01% 317
2024
Q3 		$465 Sell
1
-1
-50% -$480 ﹤0.01% 319
2024
Q2 		$937 Buy
+2
New +$868 ﹤0.01% 377

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ruedi Wealth Management's VRTX Position: Q2 2025 in Review

Ruedi Wealth Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 1 share — an estimated $485 sold.

Ruedi Wealth Management first reported a position in VRTX in Q2 2024 and held it in 4 quarters. The position peaked at $937 in Q2 2024. 1,559 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

  • Ruedi Wealth Management reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Ruedi Wealth Management sold 1 Vertex Pharmaceuticals share in Q2 2025, an estimated $485.
  • Ruedi Wealth Management first reported a position in Vertex Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Ruedi Wealth Management's Vertex Pharmaceuticals position peaked at $937 in Q2 2024.
  • 1,559 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Ruedi Wealth Management's 13F filing for Q2 2025, filed 25 Jul 2025.